SCHEMBL10006781

SCHEMBL10006781

CCN(C)C(=O)n1c(=O)n(C)c2nc(Cc3ccccc3)ncc21

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TSPO P30536 1/20 0.40
▸ RXFP1 Q9HBX9 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ FOS P01100 1/20 0.36
▸ JUN P05412 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36
▸ ADORA2B P29275 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CNOT7 Q9UIV1 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ MAOA P21397 1/20 0.34
▸ MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10006851 0.91 TRPV1 (0.36) TSPORXFP1ALDH1A1SMN1; SMN2MAOB
SCHEMBL10007610 0.90 GRIN2B (0.41) ALDH1A1MEN1KMT2ASMN1; SMN2PKM
SCHEMBL10006926 0.90 GAA (0.36) ALDH1A1SMN1; SMN2PKMMAOAMAOB
SCHEMBL10006561 0.88 MAOA (0.40) ALDH1A1MAOAMAOB
SCHEMBL10007454 0.88 GABRG2 (0.38) RXFP1ALDH1A1MEN1KMT2AMAOB
SCHEMBL10006747 0.86 MAOA (0.42) RXFP1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL10007433 0.85 FAAH (0.40) ALDH1A1SMN1; SMN2MAOAMAOB
SCHEMBL10006848 0.83 TSPO (0.52) TSPOALDH1A1MEN1KMT2AFOS
SCHEMBL10267777 0.82 TSPO (0.43) TSPOALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL10261371 0.81 TSPO (0.44) TSPORXFP1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2476682-B1 8-OXODIHYDROPURINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2017-04-26 — — EP disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US disclosed
EP-2476682-A1 8-OXODIHYDROPURINE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-07-18 — — EP disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE FAAH, FAAH2, TPMT TSPO 1233/4885RXFP1 1846/4885ALDH1A1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback